Financial Data and Key Metrics Changes - In Q4 2025, the company achieved net sales of EUR 11.3 billion, reflecting a growth of 13.3% year-over-year [6][12] - For the full year 2025, total sales reached EUR 43.6 billion, representing a 9.9% growth at constant exchange rates, which is at the upper end of the guidance [14][15] - Business EPS growth was strong at 26.7%, indicating effective operational leverage [12] - Business gross margin expanded by 1.8 percentage points to 77.5%, driven by a favorable product mix and operational efficiencies [14] Business Line Data and Key Metrics Changes - Newly launched medicines and vaccines generated EUR 5.7 billion in sales, with a growth of 34% in 2025 [4][6] - Dupixent sales reached EUR 4.2 billion in Q4 and EUR 15.7 billion for the full year, with over 30% increase in patient numbers [7][8] - Beyfortus sales grew by 9.5% to EUR 1.8 billion, driven by geographic expansion [8][9] Market Data and Key Metrics Changes - The company maintained leadership in influenza and RSV vaccines, with full-year sales of EUR 7.9 billion [8] - The U.S. market share for influenza vaccines increased, particularly with Fluzone High-Dose and Flublok [8] - Beyfortus has protected over 11 million babies in more than 45 countries, preventing an estimated 200,000 hospitalizations [9] Company Strategy and Development Direction - The company is transitioning into an R&D-driven, AI-powered biopharma entity, focusing on business development and M&A opportunities [4] - Strategic acquisitions, including Vicebio and Dynavax Technologies, are aimed at enhancing the vaccine portfolio and expanding into older adult markets [9][10][17] - The company plans to continue investing in manufacturing capacity to meet growing patient demand [14] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 to deliver high single-digit growth in sales and business EPS to grow slightly faster than sales [18] - The company anticipates a decline in vaccine sales in 2026 but expects gross margin expansion to continue [18] - Management highlighted the importance of maintaining a strong capital structure and financial flexibility for future growth opportunities [16] Other Important Information - The company completed a EUR 5 billion share buyback program and proposed a 5% increase in dividends for the 31st consecutive year [17] - The company aims for a free cash flow of at least 20% of net sales in the medium term, with a strong cash flow generation of EUR 8.1 billion in 2025 [15] Q&A Session Summary Question: Can you elaborate on the Dupixent rollout and its competition? - Management reported strong performance with 25% growth year-over-year for Dupixent, driven by new indications like CSU and COPD [30][31] - The penetration rates for Dupixent in AD and CSU are still low, indicating room for market growth [32] Question: What is the outlook for Beyfortus in 2026? - Beyfortus had a 9% increase in 2025, with expectations for continued geographic expansion [34][35] Question: What are the prospects for Amlitelimab? - Management remains confident in Amlitelimab's potential, emphasizing its novel mechanism and the importance of data-driven decisions [39][41] Question: Can you provide details on the Kaposi sarcoma case related to Amlitelimab? - Management clarified that Kaposi sarcoma is associated with herpes virus and is not considered a significant concern for Amlitelimab [46][49] Question: What is the capital allocation strategy moving forward? - The company plans to dynamically allocate resources based on value, with an increase in business development activity expected [60][75]